Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.
The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.
In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
|IPO Date||Jun 11, 2021|
11099 North Torrey Pines Road
La Jolla, CA 92037
|Phone||858 750 4700|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. David Alan Campbell Ph.D.||President, Chief Executive Officer and Director|
|Dr. Shahram Salek-Ardakani Ph.D.||Chief Scientific Officer|
|Dr. Wayne Godfrey M.D.||Chief Medical Officer|
|Tighe M. Reardon C.F.A., CPA, CPA||Acting Chief Financial Officer|
|Tommy Diraimondo Ph.D.||Director of Research|
|Andy Hollman Meyer||Chief Business Officer|
|Charles M. Winter||Senior Vice President of Chemistry, Manufacturing and Controls|
|Byron Robinson J.D., Ph.D.||Chief Strategy Officer|
Latest SEC Filings
|May 10, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|
|May 10, 2022||8-K||Current report|
|May 2, 2022||8-K||Current report|
|Apr 29, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Apr 29, 2022||DEF 14A||Other definitive proxy statements|
|Mar 18, 2022||S-8||Securities to be offered to employees in employee benefit plans|
|Mar 18, 2022||10-K||Annual report [Section 13 and 15(d), not S-K Item 405]|
|Mar 18, 2022||8-K||Current report|
|Mar 3, 2022||4||Statement of changes in beneficial ownership of securities|
|Mar 3, 2022||3||Initial statement of beneficial ownership of securities|
|View All SEC Filings|